Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Worldwide clinical experience with sultamicillin.

N E Pitts1, G S Gilbert, A K Knirsch

  • 1Department of Clinical Research, Pfizer Central Research, Groton, CT.

APMIS. Supplementum
|January 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Density and distance-to-adult effects of a canker disease of trees in a moist tropical forest.

Oecologia·2017
Same author

Geranylgeranyl-pyrophosphate, an isoprenoid of mevalonate cascade, is a critical compound for rat primary cultured cortical neurons to protect the cell death induced by 3-hydroxy-3-methylglutaryl-CoA reductase inhibition.

The Journal of neuroscience : the official journal of the Society for Neuroscience·2001
Same author

Prediction of the outcome of transtrochanteric rotational osteotomy for osteonecrosis of the femoral head.

The Journal of bone and joint surgery. British volume·2000
Same author

[HIV-1 (human immunodeficiency virus type 1) mutant strain associated with zidovudine resistance detected from a Japanese patient with primary HIV-1 infection].

Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases·2000
Same author

[New protocol for memory-related potential].

Rinsho shinkeigaku = Clinical neurology·2000
Same author

Interactions of ofloxacin and erythromycin with the multidrug resistance protein (MRP) in MRP-overexpressing human leukemia cells.

Antimicrobial agents and chemotherapy·2000
Same journal

Pseudomonas aeruginosa biofilm infections: from molecular biofilm biology to new treatment possibilities.

APMIS. Supplementum·2014
Same journal

Abstracts of the Annual Meeting of the Danish Pathology Society, 13-15 March 2014, Herlev, Denmark.

APMIS. Supplementum·2014
Same journal

The role of bacterial biofilms in chronic infections.

APMIS. Supplementum·2013
Same journal

Abstracts of the Annual Meeting of the Danish Pathology Society. March 14-16, 2013. Randers, Denmark.

APMIS. Supplementum·2013
Same journal

Abstracts of the Annual Meeting of the Danish Pathology Society. March 22-24, 2012. Copenhagen, Denmark.

APMIS. Supplementum·2012
Same journal

Rapid detection, characterization, and enumeration of foodborne pathogens.

APMIS. Supplementum·2012
See all related articles

Sultamicillin offers effective outpatient treatment for common infections, including otitis media, due to its ability to combat beta-lactamase-producing bacteria. It is a safe and well-tolerated option with minimal side effects like mild diarrhea.

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Microbiology

Background:

  • Community-acquired infections are a significant public health concern.
  • The rise of beta-lactamase-producing bacteria complicates treatment of common infections.
  • Otitis media, frequently caused by Haemophilus influenzae and Branhamella catarrhalis, often involves beta-lactamase-producing strains.

Purpose of the Study:

  • To evaluate the efficacy and safety of sultamicillin for outpatient treatment of community-acquired infections.
  • To assess sultamicillin's appropriateness for otitis media therapy in pediatric patients.
  • To explore the rationale for broad use of sultamicillin in office-based practice.

Main Methods:

  • Clinical trials assessing sultamicillin efficacy in adult and pediatric populations.

Related Experiment Videos

  • In vitro studies examining sultamicillin's activity against beta-lactamase-producing strains.
  • Analysis of laboratory parameters for systemic toxicity and side effect profiles.

    • Main Results:

    • Sultamicillin demonstrated effective outpatient therapy for respiratory, urinary, and skin/soft tissue infections.
    • It is particularly suitable for otitis media, even with beta-lactamase-producing pathogens.
    • Studies showed no evidence of systemic toxicity, with mild to moderate diarrhea as the main side effect.

    Conclusions:

    • Sultamicillin is a valuable and safe option for outpatient management of various community-acquired infections.
    • Its properties make it highly appropriate for treating otitis media in children.
    • The drug's profile supports its broad use in clinical practice, offering a superior delivery system for ampicillin.